Drugmakers Lose Bid For 'Indefinite' Extension In FTC Case
The Federal Trade Commission's pay-for-delay case against Actavis Inc. and other drugmakers is now set to resume nearly six months after the U.S. Supreme Court revived the suit, with a Georgia...To view the full article, register now.
Already a subscriber? Click here to view full article